

## **Lectin-like transcript-1 (LLT1) is a ligand for the inhibitory human NKR-P1A receptor<sup>1</sup>**

David B. Rosen<sup>\*</sup>, Jayaram Bettadapura<sup>#</sup>, Mohammed Alsharifi<sup>#</sup>, Porunelloor A. Mathew<sup>^</sup>, Hilary S. Warren<sup>2, #</sup>, and Lewis L. Lanier<sup>2, 3\*</sup>

<sup>\*</sup>Department of Microbiology and Immunology, the Cancer Research Institute, and the Biomedical Sciences Graduate Program, University of California San Francisco, CA 94143-0414; <sup>#</sup>Division of Immunology and Genetics, The John Curtin School of Medical Research, The Australian National University, Canberra City, ACT 2601, Australia; and <sup>^</sup>Department of Molecular Biology and Immunology and Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, TX 76107.

### **Abstract**

Increasingly, roles are emerging for C-type lectin-like receptors in immune regulation. One receptor whose function has remained largely enigmatic is human NKR-P1A (CD161), present on NK cells and subsets of T cells. Here we demonstrate that the Lectin-like Transcript-1 (LLT1, also named OCIL) is a physiologic ligand for NKR-P1A. LLT1-containing liposomes directly bind to NKR-P1A<sup>+</sup> cells, and binding is inhibited in the presence of anti-NKR-P1A mAb. Additionally, we show that LLT1 specifically activates NFAT-GFP reporter cells expressing a CD3 $\zeta$ -NKR-P1A chimeric receptor; reciprocally, reporter cells with a CD3 $\zeta$ -LLT1 chimeric receptor are stimulated by NKR-P1A. Moreover, our data indicate that LLT1 on target cells can inhibit NK cytotoxicity via interactions with NKR-P1A.